Micreos Raises €32M in Funding

Micreos, a The Hague, The Netherlands-based biotechnology company, secured another €32m in funding.

The company intends to use the funds to accelerate clinical development programs for atopic dermatitis, diabetic (MRSA) wounds and bloodstream infections, based on its pharmaceutical lead compounds, XZ.700 and SP.800.

Led by Mark Offerhaus, founder and CEO, Micreos develops new biological therapies based on targeted killing of only unwanted bacteria, set to replace antibiotics in a wide range of applications. Its proprietary endolysin technology has been created together with the Swiss Federal Technology Institute, ETH Zurich.

XZ.700 targets Staphylococcus aureus (S. aureus), including the antibiotic-resistant MRSA, while preserving Staphylococcus epidermidis, considered to be beneficial on the skin and conducive to wound healing. SP.800 targets all staphylococcal species.

Micreos runs its technology center in Zurich, with operations in the Netherlands and the USA. Under the Gladskin brand, the company has launched several endolysin-based OTC products for people with inflammatory skin conditions caused or aggravated by S. aureus, including acne, eczema and rosacea, and helped hundreds of thousands of people.